HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants.

AbstractAIM:
This study aims to compare the efficacy of orally administered Saccharomyces boulardii versus nystatin in prevention of fungal colonization and invasive fungal infections in very low birth weight infants.
METHOD:
A prospective, randomized comparative study was conducted in preterm infants with a gestational age of ≤ 32 weeks and birth weight of ≤ 1,500 g. They were randomized into two groups, to receive S. boulardii or nystatin. Skin and stool cultures were performed for colonization and blood cultures for invasive infections, weekly.
RESULTS:
A total of 181 infants were enrolled (S. boulardii group, n = 91; nystatin group, n = 90). Fungal colonization of the skin (15.4 vs 18.9 %, p = 0.532) and the stool (32.2 vs 27 %, p = 0.441) were not different between the probiotic and nystatin groups. Two patients had Candida-positive blood culture in the nystatin group whereas none in the probiotic group. Feeding intolerance, clinical sepsis, and number of sepsis attacks were significantly lower in the probiotics group than in the nystatin group.
CONCLUSION:
Prophylactic S. boulardii supplementation is as effective as nystatin in reducing fungal colonization and invasive fungal infection, more effective in reducing the incidence of clinical sepsis and number of sepsis attacks and has favorable effect on feeding intolerance.
AuthorsGamze Demirel, Istemi Han Celik, Omer Erdeve, Sibel Saygan, Ugur Dilmen, Fuat Emre Canpolat
JournalEuropean journal of pediatrics (Eur J Pediatr) Vol. 172 Issue 10 Pg. 1321-6 (Oct 2013) ISSN: 1432-1076 [Electronic] Germany
PMID23703468 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antifungal Agents
  • Nystatin
Topics
  • Antifungal Agents (therapeutic use)
  • Feces (microbiology)
  • Female
  • Fungi (isolation & purification)
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases (microbiology, prevention & control)
  • Infant, Very Low Birth Weight
  • Male
  • Mycoses (microbiology, prevention & control)
  • Nystatin (therapeutic use)
  • Probiotics (therapeutic use)
  • Prospective Studies
  • Saccharomyces (physiology)
  • Skin (microbiology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: